Question 1

On what does the World Health Organization (WHO)base its classification for the myelodysplastic syndromes?

Accepted Answer

A) cell morphology 
B) molecular analysis 
C) cytogenetics 
D) all of the above 
A) cell morphology 
B) molecular analysis 
C) cytogenetics 
D) all of the above D

Question 2

Myelodysplastic syndromes sometimes share similar peripheral and bone marrow cellularity with all of the following except

Accepted Answer

A) vitamin B12 deficiency 
B) aplastic anemia 
C) acute leukemia 
D) folate deficiency 
A) vitamin B12 deficiency 
B) aplastic anemia 
C) acute leukemia 
D) folate deficiency B

Question 3

All of the following are useful for determining prognosis for patients with the myelodysplastic syndromes except

Accepted Answer

A) degree of anemia 
B) cytogenetic findings 
C) number of cytopenias 
D) percent blast cells in the bone marrow 
A) degree of anemia 
B) cytogenetic findings 
C) number of cytopenias 
D) percent blast cells in the bone marrow A

Question 4

Cell dysfunction in the myelodysplastic syndromes may be present in

Accepted Answer

A) red cells 
B) granulocytes 
C) platelets 
D) all of the above 
A) red cells 
B) granulocytes 
C) platelets 
D) all of the above

Question 5

What red cell morphology is expected in the myelodysplastic syndromes?

Accepted Answer

A) oval macrocytes 
B) dimorphic 
C) hypochromic, microcytic 
D) any of the above 
A) oval macrocytes 
B) dimorphic 
C) hypochromic, microcytic 
D) any of the above

Question 6

What is the major change the WHO made to the classifications of the myelodysplastic syndromes?

Accepted Answer

A) dropped the 5q syndrome from myelodysplastic syndromes 
B) reduced the percentage of blasts required for the diagnosis of acute myeloid leukemia from 30% to 20% 
C) recognized acute myeloid leukemia as one of the myelodysplastic syndromes 
D) created a new classification placing refractory anemia and the myeloproliferative disorders together 
A) dropped the 5q syndrome from myelodysplastic syndromes 
B) reduced the percentage of blasts required for the diagnosis of acute myeloid leukemia from 30% to 20% 
C) recognized acute myeloid leukemia as one of the myelodysplastic syndromes 
D) created a new classification placing refractory anemia and the myeloproliferative disorders together

Question 7

Which of the following is a common feature of the myelodysplastic syndromes?

Accepted Answer

A) peripheral blasts between 5% and 20% 
B) progressive cytopenias and dyspoiesis in one or more cell lines 
C) macrocytic red cells and leukocytosis 
D) low mean cell volume (MCV) and thrombocytopenia 
A) peripheral blasts between 5% and 20% 
B) progressive cytopenias and dyspoiesis in one or more cell lines 
C) macrocytic red cells and leukocytosis 
D) low mean cell volume (MCV) and thrombocytopenia

Question 8

What test is most important in distinguishing one myelodysplastic syndrome from another?

Accepted Answer

A) white blood count 
B) percentage of blasts in the bone marrow 
C) red cell morphology and MCV 
D) presence of ringed sideroblasts in the peripheral blood 
A) white blood count 
B) percentage of blasts in the bone marrow 
C) red cell morphology and MCV 
D) presence of ringed sideroblasts in the peripheral blood

Question 9

Which of the following would be an unexpected finding in myelodysplastic syndrome with a deletion of 5q?

Accepted Answer

A) refractory anemia 
B) thrombocytosis 
C) less than 1% blasts in peripheral blood 
D) Auer rods 
A) refractory anemia 
B) thrombocytosis 
C) less than 1% blasts in peripheral blood 
D) Auer rods

Question 10

Therapy-related myelodysplastic syndrome follows what type of treatment?

Accepted Answer

A) certain antibiotic agents for severe infection 
B) human growth factors such as CSF-GM 
C) corticosteroid agents for immune disorders 
D) chemotherapy and radiation for cancer 
A) certain antibiotic agents for severe infection 
B) human growth factors such as CSF-GM 
C) corticosteroid agents for immune disorders 
D) chemotherapy and radiation for cancer

Question 11

Which of following is an expected finding in myelodysplastic syndromes?

Accepted Answer

A) ringed sideroblasts in the bone marrow and siderocytes in the blood 
B) thrombocytosis and leukocytosis 
C) increased number of morphologically normal red cells 
D) dysmyelopoiesis but normal red cell precursors in the bone marrow 
A) ringed sideroblasts in the bone marrow and siderocytes in the blood 
B) thrombocytosis and leukocytosis 
C) increased number of morphologically normal red cells 
D) dysmyelopoiesis but normal red cell precursors in the bone marrow

Question 12

What treatment for the myelodysplastic syndromes has the best chance for cure in these patients?

Accepted Answer

A) corticosteroid agents 
B) chemotherapy 
C) bone marrow transplant 
D) vitamins and hormones 
A) corticosteroid agents 
B) chemotherapy 
C) bone marrow transplant 
D) vitamins and hormones

Question 13

Which of the following is true regarding the clinical course of the myelodysplastic syndromes?

Accepted Answer

A) The course is variable based on cell counts and type of myelodysplastic syndrome. 
B) Most patients survive an average of 10 years with minimal symptoms. 
C) It has an aggressive course with most patients succumbing to infection in less than 1 year. 
D) All cases convert to acute leukemia. 
A) The course is variable based on cell counts and type of myelodysplastic syndrome. 
B) Most patients survive an average of 10 years with minimal symptoms. 
C) It has an aggressive course with most patients succumbing to infection in less than 1 year. 
D) All cases convert to acute leukemia.

Question 14

What is the cause of myelodysplastic syndromes?

Accepted Answer

A) decreased apoptosis 
B) are inherited disorders 
C) proliferation of mutated myeloid cells 
D) Epstein-Barr virus 
A) decreased apoptosis 
B) are inherited disorders 
C) proliferation of mutated myeloid cells 
D) Epstein-Barr virus

Question 15

Which of the following is a typical finding in chronic myelomonocytic leukemia?

Accepted Answer

A) thrombocytosis 
B) leukopenia 
C) 10% to 15% blasts in the peripheral blood 
D) absolute monocytosis 
A) thrombocytosis 
B) leukopenia 
C) 10% to 15% blasts in the peripheral blood 
D) absolute monocytosis

Question 16

Which of the following is typical in the peripheral blood in patients with myelodysplastic syndrome?

Accepted Answer

A) lymphocytosis 
B) plasma cells 
C) hypogranular or agranular neutrophils 
D) low levels of vitamin B12 or folate 
A) lymphocytosis 
B) plasma cells 
C) hypogranular or agranular neutrophils 
D) low levels of vitamin B12 or folate

Exam 34: Myelodysplastic Syndromes

On what does the World Health Organization (WHO)base its classification for the myelodysplastic syndromes?

Myelodysplastic syndromes sometimes share similar peripheral and bone marrow cellularity with all of the following except

All of the following are useful for determining prognosis for patients with the myelodysplastic syndromes except

Cell dysfunction in the myelodysplastic syndromes may be present in

What red cell morphology is expected in the myelodysplastic syndromes?

What is the major change the WHO made to the classifications of the myelodysplastic syndromes?

Which of the following is a common feature of the myelodysplastic syndromes?

What test is most important in distinguishing one myelodysplastic syndrome from another?

Which of the following would be an unexpected finding in myelodysplastic syndrome with a deletion of 5q?

Therapy-related myelodysplastic syndrome follows what type of treatment?

Which of following is an expected finding in myelodysplastic syndromes?

What treatment for the myelodysplastic syndromes has the best chance for cure in these patients?

Which of the following is true regarding the clinical course of the myelodysplastic syndromes?

What is the cause of myelodysplastic syndromes?

Which of the following is a typical finding in chronic myelomonocytic leukemia?

Which of the following is typical in the peripheral blood in patients with myelodysplastic syndrome?

An Overview of Clinical Laboratory Hematology

Safety in the Hematology Laboratory

Blood Specimen Collection

Care and Use of the Microscope

Quality Assurance in Hematology and Hemostasis Testing

Cellular Structure and Function

Hematopoiesis

Erythrocyte Production and Destruction

Erythrocyte Metabolism and Membrane Structure and Function

Hemoglobin Metabolism

Iron Kinetics and Laboratory Assessment

Leukocyte Development, Kinetics, and Functions

Platelet Production, Structure, and Function

Manual, Semiautomated and Point-of-Care Testing in Hematology

Automated Blood Cell Analysis

Examination of the Peripheral Blood Film and Correlation with the Complete Blood Count

Bone Marrow Examination

Body Fluid Analysis in the Hematology Laboratory

Anemias: Red Blood Cell Morphology and Approach to Diagnosis

Disorders of Iron Kinetics and Heme Metabolism

Anemias Caused by Defects of DNA Metabolism

Bone Marrow Failure

Introduction to Increased Destruction of Erythrocytes

Intrinsic Defects Leading to Increased Erythrocyte Destruction

Extrinsic Defects Leading to Increased Erythrocyte Destruction Nonimmune Causes

Extrinsic Defects Leading to Increased Erythrocyte Destruction Immune Causes

Hemoglobinopathies (Structural Defects in Hemoglobin)

Thalassemias

Nonmalignant Leukocyte Disorders

Cytogenetics

Molecular Diagnostics in Hematopathology

Flow Cytometric Analysis in Hematologic Disorders

Myeloproliferative Neoplasms

Acute Leukemias

Mature Lymphoid Neoplasms

Normal Hemostasis and Coagulation

Hemorrhagic Disorders and Laboratory Assessment

Thrombotic Disorders and Laboratory Assessment

Thrombocytopenia and Thrombocytosis

Qualitative Disorders of Platelets and Vasculature

Laboratory Evaluation of Hemostasis

Antithrombotic Therapies and their Laboratory Assessment

Hemostasis and Coagulation Instrumentation

Pediatric and Geriatric Hematology and Hemostasis

Filters